Literature DB >> 19435722

New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?

David L Scott, Andrew Cope.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19435722     DOI: 10.1136/ard.2008.105940

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

1.  Therapy: what should we do after the failure of a first anti-TNF?

Authors:  Chris Deighton
Journal:  Nat Rev Rheumatol       Date:  2009-11       Impact factor: 20.543

Review 2.  Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Authors:  Matthew B Carroll; Michael A Forgione
Journal:  Clin Rheumatol       Date:  2010-06-16       Impact factor: 2.980

Review 3.  Certolizumab in the long-term treatment of rheumatoid arthritis.

Authors:  Abdul Khan; David L Scott
Journal:  Open Access Rheumatol       Date:  2011-08-25

4.  Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.

Authors:  Stanley B Cohen; Alberto Alonso-Ruiz; Piotr A Klimiuk; Eric C Lee; Nuala Peter; Ivo Sonderegger; Deepak Assudani
Journal:  Ann Rheum Dis       Date:  2018-03-07       Impact factor: 27.973

5.  Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs.

Authors:  Manil Kukar; Olga Petryna; Petros Efthimiou
Journal:  Biologics       Date:  2009-10-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.